|
1）Wang Z, Li Y, Sarkar FH. Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci. 2010; 11: 398-408
|
|
|
|
2）Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999; 284: 770-6
|
|
|
|
|
|
3）Cheng HT, Miner JH, Lin M, et al. Gamma-secretase activity is dispensable for mesenchyme-to-epithelium transition but required for podocyte and proximal tubule formation in developing mouse kidney. Development. 2003; 130: 5031-42
|
|
|
|
|
|
4）Cheng HT, Kim M, Valerius MT, et al. Notch 2, but not Notch 1, is required for proximal fate acquisition in the mammalian nephron. Development. 2007; 134: 801-11
|
|
|
|
|
|
5）Fujimura S, Jiang Q, Kobayashi C, et al. Notch 2 activation in the embryonic kidney depletes nephron progenitors. J Am Soc Nephrol. 2010; 21: 803-10
|
|
|
|
|
|
6）Kopan R, Chen S, Liu Z. Alagille, Notch, and robustness: why duplicating systems does not ensure redundancy. Pediatr Nephrol. 2014; 29: 651-7
|
|
|
|
|
|
7）Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med. 2008; 14: 290-8
|
|
|
|
|
|
8）Lasagni L, Ballerini L, Angelotti ML, et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells. 2010; 28: 1674-85
|
|
|
|
|
|
9）Waters AM, Wu MY, Onay T, et al. Ectopic notch activation in developing podocytes causes glomerulosclerosis. J Am Soc Nephrol. 2008; 19: 1139-57
|
|
|
|
|
|
10）Waters AM, Wu MY, Huang YW, et al. Notch promotes dynamin-dependent endocytosis of nephrin. J Am Soc Nephrol. 2012; 23: 27-35
|
|
|
|
|
|
11）Murea M, Park JK, Sharma S, et al. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int. 2010; 78: 514-22
|
|
|
|
|
|
12）Sharma M, Callen S, Zhang D, et al. Activation of Notch signaling pathway in HIV-associated nephropathy. Aids. 2010; 24: 2161-70
|
|
|
|
|
|
13）Sharma M, Magenheimer LK, Home T, et al. Inhibition of Notch pathway attenuates the progression of human immunodeficiency virus-associated nephropathy. Am J Physiol Ren Physiol. 2013; 304: F1127-36
|
|
|
|
|
|
14）Ueno T, Kobayashi N, Nakayama M, et al. Aberrant Notch 1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int. 2013; 83: 1065-75
|
|
|
|
|
|
15）Tanaka E, Asanuma K, Kim E, et al. Notch 2 activation ameliorates nephrosis. Nat Commun. 2014; 5: 3296
|
|
|
|
|
|
16）Morito N, Yoh K, Ojima M, et al. Overexpression of Mafb in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2014; 25: 2546-57
|
|
|
|
|
|
17）Wang XM, Yao M, Liu SX, et al. Interplay between the Notch and PI3K/Akt pathways in high glucose-induced podocyte apoptosis. Am J Physiol Ren Physiol. 2014; 306: F205-13
|
|
|
|
|
|
18）El Machhour F, Keuylian Z, Kavvadas P, et al. Activation of Notch 3 in glomeruli promotes the development of rapidly progressive renal disease. J Am Soc Nephrol. 2015; 26: 1561-75
|
|
|
|
|